Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Robert L. Ferris, Robert I. Haddad, Caroline Even, +17

Annals of Oncology

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC

Lillian L. Siu, Caroline Even, Éva Remenár, +16

JAMA Oncology

Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

Khalil Saleh, Amaury Daste, Nicolas Martin, +9

European Journal of Cancer

MedicineImmune Checkpoint InhibitorsImmunologyPathologyImmune Checkpoint Inhibitor +6

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

Robert I. Haddad, Kevin J. Harrington, Makoto Tahara, +22

Journal of Clinical Oncology

A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study

Alain Ravaud, Christelle de la Fouchardière, Philippe Caron, +16

European Journal of Cancer

Thysu StudyMedicineMedullary Thyroid CarcinomasThyroid DiseaseMature Data +5

Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events

Marie Kostine, Eleonora Mauric, Alice Tison, +18

European Journal of Cancer

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort

Byoung Chul Cho, Amaury Daste, Alain Ravaud, +10

Journal for ImmunoTherapy of Cancer

A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial

Rachel Galot, Christophe Le Tourneau, Esma Saâda-Bouzid, +22

European Journal of Cancer

Eortc-hncg-1559 Upstream TrialMalignant DiseaseMedicinePathologyPhase Ii Study +6

EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Lisa Licitra, Robert I. Haddad, Caroline Even, +15

Journal of Clinical Oncology

D Vs SocR/m HnsccPathologyPharmacotherapyImmunotherapy +21

LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

Athanassios Argiris, Kevin J. Harrington, Makoto Tahara, +16

Annals of Oncology

Lba36 NivolumabNeoadjuvant TherapyMedicinePathologyImmune Checkpoint Inhibitor +9